CA2620534A1 - Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments - Google Patents

Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments

Info

Publication number
CA2620534A1
CA2620534A1 CA002620534A CA2620534A CA2620534A1 CA 2620534 A1 CA2620534 A1 CA 2620534A1 CA 002620534 A CA002620534 A CA 002620534A CA 2620534 A CA2620534 A CA 2620534A CA 2620534 A1 CA2620534 A1 CA 2620534A1
Authority
CA
Canada
Prior art keywords
pyridazin
imidazo
amine
alkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002620534A
Other languages
English (en)
Other versions
CA2620534C (fr
Inventor
Olaf Prien
Benjamin Bader
Ulrich Zuegel
Stuart James Ince
Christoph Huwe
Karina Schuck
Knut Eis
Ulrich Luecking
Rolf Jautelat
Judith Guenther
Manfred Husemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2620534A1 publication Critical patent/CA2620534A1/fr
Application granted granted Critical
Publication of CA2620534C publication Critical patent/CA2620534C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2620534A 2005-09-02 2006-09-01 Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments Expired - Fee Related CA2620534C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005042742A DE102005042742A1 (de) 2005-09-02 2005-09-02 Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005042742.1 2005-09-02
PCT/DE2006/001564 WO2007025540A2 (fr) 2005-09-02 2006-09-01 Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments

Publications (2)

Publication Number Publication Date
CA2620534A1 true CA2620534A1 (fr) 2007-03-08
CA2620534C CA2620534C (fr) 2014-05-27

Family

ID=37709434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2620534A Expired - Fee Related CA2620534C (fr) 2005-09-02 2006-09-01 Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments

Country Status (5)

Country Link
EP (1) EP2176266A2 (fr)
JP (1) JP5680824B2 (fr)
CA (1) CA2620534C (fr)
DE (1) DE102005042742A1 (fr)
WO (1) WO2007025540A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012325911B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9499547B2 (en) 2011-09-06 2016-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
KR20090047509A (ko) * 2006-08-04 2009-05-12 다케다 야쿠힌 고교 가부시키가이샤 융합 헤테로시클릭 유도체 및 이의 용도
US20110021513A1 (en) * 2006-09-07 2011-01-27 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
CA2667962A1 (fr) * 2006-10-30 2008-05-08 Novartis Ag Composes heterocycliques en tant qu'agents anti-inflammatoires
JP5357763B2 (ja) 2006-11-06 2013-12-04 トレロ ファーマシューティカルズ， インコーポレイテッド イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
CA2686485A1 (fr) 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones et 1h-imidazopyridinones en tant qu'inhibiteurs de pkc-theta
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
WO2009062059A2 (fr) * 2007-11-08 2009-05-14 Pharmacopeia, Inc. Purinones et 1h-imidazopyridinones isomères comme inhibiteurs de pkc-thêta
EP2217601A1 (fr) * 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
MX2010012457A (es) * 2008-05-13 2010-12-07 Irm Llc Heterociclos que contienen nitrogeno fusionado y composiciones de los mismos como inhibidores de cinasa.
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
TWI577680B (zh) 2008-10-22 2017-04-11 亞雷生物製藥股份有限公司 作為ＴＲＫ激酶抑制劑之經取代吡唑并〔１，５－ａ〕嘧啶化合物
FR2939134A1 (fr) 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2210891A1 (fr) * 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
US8729074B2 (en) * 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
EP2430013B1 (fr) * 2009-05-13 2014-10-15 Amgen Inc. Composés heteraryles comme inhibiteurs de la pikk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
GB201002911D0 (en) * 2010-02-19 2010-04-07 Medical Res Council Compound
ES2534335T3 (es) 2010-05-20 2015-04-21 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la Trk cinasa
GB201104669D0 (en) * 2011-03-18 2011-05-04 Medical Res Council Technology Compound
EP2710004A1 (fr) 2011-05-17 2014-03-26 Bayer Intellectual Property GmbH Imidazopyridazines amino-substituées en tant qu'inhibiteurs de kinase mknk1
EP2714652B8 (fr) 2011-05-27 2018-09-05 Ardea Biosciences, Inc. Synthèse chirale de n-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
EP2714692B1 (fr) * 2011-06-01 2017-03-22 Bayer Intellectual Property GmbH Aminoimidazopyridazines substituées
WO2012175591A1 (fr) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Hétérocyclylaminoimidazopyridazines
WO2013004551A1 (fr) * 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
EP2731439A4 (fr) 2011-07-12 2014-12-03 Merck Sharp & Dohme INHIBITEURS DE LA KINASE TrkA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
CN103814029B (zh) 2011-09-23 2016-10-12 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
DK2760867T3 (en) * 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
EP2760453B1 (fr) * 2011-09-30 2016-05-25 Ipsen Pharma S.A.S. Inhibiteurs macrocycliques de la kinase lrrk2
CN104114559B (zh) 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
EP2858993B1 (fr) 2012-03-29 2018-01-10 Bayer Intellectual Property GmbH Imidazopyridazines substituées par amino
WO2013149909A1 (fr) 2012-04-04 2013-10-10 Bayer Pharma Aktiengesellschaft Imidazopyridazines amino-substituées
EP2858501A4 (fr) 2012-05-22 2015-12-09 Merck Sharp & Dohme Inhibiteurs de kinase trk-a, compositions et méthodes correspondantes
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
ES2646916T3 (es) * 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
US20160287589A1 (en) 2013-02-20 2016-10-06 Bayer Pharma Aktiengesellschaft Substituted-imidazopyridazines
US9370515B2 (en) 2013-03-07 2016-06-21 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
JP6409055B2 (ja) 2013-05-20 2018-10-17 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーションＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｗａｓｈｉｎｇｔｏｎ Ｔｈｒｏｕｇｈ Ｉｔｓ Ｃｅｎｔｅｒ Ｆｏｒ Ｃｏｍｍｅｒｃｉａｌｉｚａｔｉｏｎ Ｃｄｐｋ１の５−アミノピラゾール−４−カルボキサミド阻害剤
WO2015039333A1 (fr) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
WO2015039334A1 (fr) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions en contenant et procédés correspondants
CN105899512A (zh) 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
MX2018005087A (es) 2015-10-26 2019-05-16 Loxo Oncology Inc Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas.
JP7061602B2 (ja) 2016-04-04 2022-04-28 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3458456T3 (da) 2016-05-18 2020-12-14 Array Biopharma Inc Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP6916562B2 (ja) 2017-08-11 2021-08-11 テリジーン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ． 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
US11236086B2 (en) * 2017-10-18 2022-02-01 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN110734437B (zh) * 2018-07-19 2022-04-08 南京烁慧医药科技有限公司 吡唑并嘧啶化合物和药物组合物及其应用
CA3127502A1 (fr) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
WO2020187291A1 (fr) 2019-03-19 2020-09-24 华中师范大学 Composé de pyrazolopyrimidine, composition pharmaceutique et utilisation associée
CN111718351B (zh) * 2019-03-19 2021-10-12 华中师范大学 含氧取代吡唑并嘧啶化合物和药物组合物及其应用
CN111718350B (zh) * 2019-03-19 2021-04-13 华中师范大学 吡唑取代的吡唑并嘧啶化合物和药物组合物及其应用
CN111718349B (zh) * 2019-03-19 2021-11-02 华中师范大学 含氟吡唑并嘧啶化合物和药物组合物及其应用
EP3967696A4 (fr) * 2019-05-08 2023-08-09 TYK Medicines Inc. Composé utilisé comme inhibiteur de kinase et son application
CN114437077B (zh) * 2020-11-04 2024-01-30 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542661A1 (de) * 1985-12-03 1987-06-04 Bayer Ag Imidazopyridazinalkensaeureamide, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung
AU7079998A (en) * 1997-04-25 1998-11-24 Takeda Chemical Industries Ltd. Condensed pyridazine derivatives, their production and use
SE9800835D0 (sv) * 1998-03-13 1998-03-13 Astra Ab New Compounds
PL354241A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
AU3740101A (en) * 2000-03-01 2001-09-12 Janssen Pharmaceutica Nv 2,4-disubstituted thiazolyl derivatives
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
MXPA05006478A (es) * 2002-12-18 2005-09-08 Vertex Pharma Triazolopiridazinas como inhibidores de proteinas cinasas.
NZ548098A (en) * 2003-12-31 2010-05-28 Schering Plough Ltd Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
JP2009502734A (ja) * 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499547B2 (en) 2011-09-06 2016-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
AU2012325911B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators

Also Published As

Publication number Publication date
JP2009506993A (ja) 2009-02-19
WO2007025540A2 (fr) 2007-03-08
EP2176266A2 (fr) 2010-04-21
CA2620534C (fr) 2014-05-27
DE102005042742A1 (de) 2007-03-08
JP5680824B2 (ja) 2015-03-04
WO2007025540A3 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
CA2620534A1 (fr) Imidazo[1,2b]pyridazines substituees constituant des inhibiteurs de kinases, leur production et leur utilisation comme medicaments
US7750000B2 (en) Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
AU2003270318B2 (en) Imidazolopyridines and methods of making and using the same
EP2536722B1 (fr) Composés bicycliques et utilisations associées en tant qu'inhibiteurs mixtes de c-src/jak
KR100737259B1 (ko) 이미다조[1,2-ａ]피리딘 및 피라졸로[2,3-ａ]피리딘 유도체
CA2821546C (fr) Derives de 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, et 2-phenylimidazo[1,2-a]pyrazine
CN110551105B (zh) 用作axl抑制剂的取代三唑
CA2656419C (fr) Pyrazolopyrimidines et leurs sels, compositions pharmaceutiques les comprenant, procedes de preparation de celles-ci et leurs utilisations
AU2009288399A1 (en) Hedgehog pathway modulators
JP2006502164A5 (fr)
HRP960316A2 (en) Heterocyclic compounds
WO2006073610A2 (fr) Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
AU2010204106A1 (en) Compounds for the prevention and treatment of cardiovascular disease
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
IL191213A (en) Transformed derivatives in the cycles of pyrimidone
WO2014106800A2 (fr) Dérivés de pyrimidine à substitution 2-amino servant de composés inhibiteurs de kinase
CA3147422A1 (fr) Inhibiteurs de kinases dependantes des cyclines
CN114072148A (zh) Raf激酶的抑制剂
CN110950867A (zh) 一种fgfr4激酶抑制剂及其制备方法和用途
TW202244049A (zh) Shp2磷酸酶抑制劑的製備及其應用
JP2009501176A (ja) グリコーゲンシンターゼキナーゼ３阻害薬としてのピリダジン化合物
CN115151550A (zh) 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途
CN117229292A (zh) Ret抑制剂的制备及其应用
CN116063324A (zh) 具有大环结构的btk和/或ret抑制剂

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160901